Margaret Brimble

Dame Margaret Brimble FRS is a Distinguished Professor at the University of Auckland, New Zealand and Past-President of IUPAC Dvision II Organic and Biomolecular Chemistry. Her research focusses on the synthesis of novel bioactive natural products, antimicrobial and antiviral peptides, antibody-drug conjugates, lipopeptides for vaccines and new biomaterials. Her lab led the medicinal chemistry programme that discovered the drug trofinetide (NNZ2566) that gained FDA approval (marketed as DaybueTM) in March 2023 for the treatment of Rett Syndrome (http://www.neurenpharma.com; https://acadia.com) and NNZ2591 that is currently in phase 2 clinical trials for four neurogenetic disorders. She is an Executive Editor for Organic Letters, has published over 700 papers and named an inventor of 50+ patent families. Selected awards include: 2023 Royal Society London Davy Medal, 2023 ACS Ernest Guenther Award for Natural Products, 2022 RSC Pedler Award for Research & Innovation in Organic Chemistry, 2023 Medicines NZ Award for Excellence in Innovative Medicines Research and the  Royal Society NZ Rutherford, Hector and MacDiarmid Medals (2012).